[ad_1] ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced […]
[ad_1] FRANKFURT, Germany, Dec. 9, 2024 /PRNewswire/ — Zentiva AG, a wholly-owned subsidiary of Zentiva Pharma GmbH, headquartered in Frankfurt am Main, Germany, and part of Zentiva group (“Zentiva”), completed the voluntary public purchase offer […]
[ad_1] Studies show promising new options to address unmet needs in sickle cell disease and immune thrombocytopenia SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — Researchers report significant progress toward expanding the therapeutic options available for people […]
[ad_1] 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) […]
[ad_1] NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ — Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries […]
